Zoetis price target raised to $210 from $200 at Stifel

Stifel raised the firm’s price target on Zoetis (ZTS) to $210 from $200 and keeps a Buy rating on the shares. Investors have been concerned about pending competition to Trio, notably Merck’s (MRK) Bravecto Quantum, but after having surveyed vets in the U.S. and Australia the firm says it views Quantum feedback as “relatively underwhelming,” giving Stifel increased confidence that Trio may act as an upside lever in 2025/2026.